Vistagen Therapeutics, Inc. — Form 8-K
Filed September 25, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Vistagen Therapeutics presented September 2026 corporate data on fasedienol (social anxiety disorder), itruvone (major depressive disorder), refisolone (menopausal hot flashes/PMDD), and earlier-stage candidates. PALISADE-2 Phase 3 met primary endpoint (p=0.015, 13.8-point SUDS reduction vs. 8.0 placebo); three other Phase 3 trials (PALISADE-1, -3, -4) did not meet their primary SUDS endpoints, though post-hoc analysis of very severe SAD subpopulation showed significance (p=0.036). Company proposes advancing an LSAS-based Phase 3 study (n=350, 6-week treatment) for everyday-life social anxiety measurement rather than acute challenge testing. No financing, partnership, or material corporate transaction disclosed.
Why this rating
Mixed Phase 3 efficacy (1 of 4 studies positive; post-hoc salvage analysis); proposed new pivotal study adds regulatory uncertainty. At $137.7M market cap, clinical progress is meaningful but mixed results and shift in endpoints weigh against transformational impact. No capital event or major deal.
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.